NASDAQ Framework: Lantheus Holdings Inc.

Radiopharmaceuticals, diagnostics, therapeutics, AI solutions 1.

Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products to assist clinicians in the diagnosis and treatment of cardiovascular diseases, cancer, and other conditions worldwide 2. The company offers a broad portfolio of products, including PYLARIFY®, a PSMA PET imaging agent for prostate cancer detection; DEFINITY®, an ultrasound enhancing agent; and TechneLite®, a technetium-based generator for nuclear medicine procedures 3. Lantheus is also committed to innovation in artificial intelligence, providing solutions like PYLARIFY AI™ for the evaluation of PSMA PET images 4. Founded in 1956 and headquartered in Bedford, Massachusetts, Lantheus continues to expand its pipeline and capabilities through strategic acquisitions and partnerships 5 6.

2: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source3: Lantheus provides a broad portfolio of products, including PYLARIFY® (Piflufolastat F18), a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound enhancing agent for patients with suboptimal echocardiograms; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and AZEDRA® (Iobenguane I 131) for the treatment of certain rare neuroendocrine tumors. View Source4: Lantheus provides a broad portfolio of products, including PYLARIFY® (Piflufolastat F18), a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound enhancing agent for patients with suboptimal echocardiograms; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and AZEDRA® (Iobenguane I 131) for the treatment of certain rare neuroendocrine tumors. View Source5: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source6: Lantheus acquires Meilleur Technologies, gaining Alzheimer's imaging agent candidate View Source

NO

Lantheus Holdings, Inc. was founded in 1956, and there is no information indicating that the founders are still leading the company or heavily involved 7 8 9.

7: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source8: Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA. View Source9: Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA. View Source

LOW RISK

Lantheus Holdings, Inc. is considered to have a low financial risk. The company has shown strong revenue projections and strategic expansion, particularly with the acquisition of Meilleur Technologies and the positive adjustment in sales trajectory for PYLARIFY due to recent CMS rule changes 10 11. Furthermore, multiple analysts have reaffirmed their Buy ratings on the stock, indicating confidence in its financial health and future prospects 12 13 14. The company's diversified portfolio of diagnostic and therapeutic products, along with its commitment to innovation in artificial intelligence, also supports its stable financial outlook 15 16 17.

10: Justin Walsh has given his Buy rating due to a combination of factors that underscore Lantheus Holdings, Inc.’s promising outlook. The recent proposed changes to the CMS rules have led to a positive adjustment in the sales trajectory for PYLARIFY, Lantheus’s diagnostic agent, which has improved the company’s future revenue projections. Walsh’s confidence is solidified by a risk-adjusted discounted cash flow analysis, which suggests an increase in the fair market capitalization of Lantheus, prompting an increase in the 12-month price target for the stock from $128 to $137. Moreover, the strategic acquisition of Meilleur Technologies by Lantheus is indicative of the company’s commitment to expanding its portfolio and pipeline, particularly within the therapeutic radiopharmaceutical space. This expansion is expected to be a key driver of medium- to long-term value. Despite the CMS rule changes benefiting PYLARIFY sales, Walsh emphasizes that the company’s growth potential lies in its therapeutic offerings, which are projected to account for a significant portion of future revenues—underscoring the company’s promising financial trajectory and justifying the Buy rating. View Source11: Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease Lantheus announces acquisition of Meilleur Technologies, NAV-4694 Lantheus price target raised to $165 from $100 at Mizuho Top Stock Gainers Today – QS, JOBY, and More View Source12: TD Cowen Remains a Buy on Lantheus (LNTH)July 23, 2024TipRanksJefferies Reaffirms Their Buy Rating on Lantheus (LNTH)July 19, 2024TipRanksLantheus price target raised to $137 from $128 at JonesResearchJuly 18, 2024TipRanksBuy Rating Affirmed for Lantheus Holdings with Enhanced Revenue Projections and Strategic ExpansionJuly 18, 2024TipRanksLantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern TimeJuly 17, 2024TipRanks View Source13: TD Cowen Remains a Buy on Lantheus (LNTH) View Source14: Jefferies Reaffirms Their Buy Rating on Lantheus (LNTH) View Source15: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source16: Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in... View Source17: Lantheus provides a broad portfolio of products, including PYLARIFY® (Piflufolastat F18), a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound enhancing agent for patients with suboptimal echocardiograms; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and AZEDRA® (Iobenguane I 131) for the treatment of certain rare neuroendocrine tumors. View Source

YES

Lantheus Holdings, Inc. is launching new product offerings, including the acquisition of NAV-4694, a next-generation ß Amyloid PET imaging agent for Alzheimer's disease, and the expansion of its portfolio with the acquisition of Meilleur Technologies 18 19 20.

18: Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease Lantheus announces acquisition of Meilleur Technologies, NAV-4694 Lantheus price target raised to $165 from $100 at Mizuho Top Stock Gainers Today – QS, JOBY, and More View Source19: Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease View Source20: Lantheus acquires Meilleur Technologies, gaining Alzheimer's imaging agent candidate View Source

Lantheus Holdings, Inc. is strategically expanding its product roadmap and capabilities from 2024 through 2026 through a series of strategic acquisitions and innovations. The company has recently acquired Meilleur Technologies and NAV-4694, a next-generation ß Amyloid PET imaging agent for Alzheimer's disease, which significantly strengthens its diagnostic capabilities in neurodegenerative diseases 21 22. Additionally, Lantheus is focusing on enhancing its therapeutic radiopharmaceutical portfolio, particularly in prostate and breast cancers, with the acquisition of global rights to Life Molecular Imaging’s novel therapeutic and diagnostic pair targeting GRPR 23. The company is also leveraging artificial intelligence to improve diagnostic accuracy and patient outcomes, as evidenced by the integration of its AI-enabled aPROMISE solution on Siemens Healthineers’ syngo.via platform 24. These strategic moves are expected to drive medium- to long-term value and support the company's growth trajectory 25.

21: Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease Lantheus announces acquisition of Meilleur Technologies, NAV-4694 Lantheus price target raised to $165 from $100 at Mizuho Top Stock Gainers Today – QS, JOBY, and More View Source22: Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease View Source23: Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers View Source24: Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform View Source25: Justin Walsh has given his Buy rating due to a combination of factors that underscore Lantheus Holdings, Inc.’s promising outlook. The recent proposed changes to the CMS rules have led to a positive adjustment in the sales trajectory for PYLARIFY, Lantheus’s diagnostic agent, which has improved the company’s future revenue projections. Walsh’s confidence is solidified by a risk-adjusted discounted cash flow analysis, which suggests an increase in the fair market capitalization of Lantheus, prompting an increase in the 12-month price target for the stock from $128 to $137. Moreover, the strategic acquisition of Meilleur Technologies by Lantheus is indicative of the company’s commitment to expanding its portfolio and pipeline, particularly within the therapeutic radiopharmaceutical space. This expansion is expected to be a key driver of medium- to long-term value. Despite the CMS rule changes benefiting PYLARIFY sales, Walsh emphasizes that the company’s growth potential lies in its therapeutic offerings, which are projected to account for a significant portion of future revenues—underscoring the company’s promising financial trajectory and justifying the Buy rating. View Source

Sources

1: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source2: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source3: Lantheus provides a broad portfolio of products, including PYLARIFY® (Piflufolastat F18), a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound enhancing agent for patients with suboptimal echocardiograms; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and AZEDRA® (Iobenguane I 131) for the treatment of certain rare neuroendocrine tumors. View Source4: Lantheus provides a broad portfolio of products, including PYLARIFY® (Piflufolastat F18), a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound enhancing agent for patients with suboptimal echocardiograms; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and AZEDRA® (Iobenguane I 131) for the treatment of certain rare neuroendocrine tumors. View Source5: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source6: Lantheus acquires Meilleur Technologies, gaining Alzheimer's imaging agent candidate View Source7: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source8: Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA. View Source9: Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA. View Source10: Justin Walsh has given his Buy rating due to a combination of factors that underscore Lantheus Holdings, Inc.’s promising outlook. The recent proposed changes to the CMS rules have led to a positive adjustment in the sales trajectory for PYLARIFY, Lantheus’s diagnostic agent, which has improved the company’s future revenue projections. Walsh’s confidence is solidified by a risk-adjusted discounted cash flow analysis, which suggests an increase in the fair market capitalization of Lantheus, prompting an increase in the 12-month price target for the stock from $128 to $137. Moreover, the strategic acquisition of Meilleur Technologies by Lantheus is indicative of the company’s commitment to expanding its portfolio and pipeline, particularly within the therapeutic radiopharmaceutical space. This expansion is expected to be a key driver of medium- to long-term value. Despite the CMS rule changes benefiting PYLARIFY sales, Walsh emphasizes that the company’s growth potential lies in its therapeutic offerings, which are projected to account for a significant portion of future revenues—underscoring the company’s promising financial trajectory and justifying the Buy rating. View Source11: Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease Lantheus announces acquisition of Meilleur Technologies, NAV-4694 Lantheus price target raised to $165 from $100 at Mizuho Top Stock Gainers Today – QS, JOBY, and More View Source12: TD Cowen Remains a Buy on Lantheus (LNTH)July 23, 2024TipRanksJefferies Reaffirms Their Buy Rating on Lantheus (LNTH)July 19, 2024TipRanksLantheus price target raised to $137 from $128 at JonesResearchJuly 18, 2024TipRanksBuy Rating Affirmed for Lantheus Holdings with Enhanced Revenue Projections and Strategic ExpansionJuly 18, 2024TipRanksLantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern TimeJuly 17, 2024TipRanks View Source13: TD Cowen Remains a Buy on Lantheus (LNTH) View Source14: Jefferies Reaffirms Their Buy Rating on Lantheus (LNTH) View Source15: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. View Source16: Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in... View Source17: Lantheus provides a broad portfolio of products, including PYLARIFY® (Piflufolastat F18), a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound enhancing agent for patients with suboptimal echocardiograms; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and AZEDRA® (Iobenguane I 131) for the treatment of certain rare neuroendocrine tumors. View Source18: Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease Lantheus announces acquisition of Meilleur Technologies, NAV-4694 Lantheus price target raised to $165 from $100 at Mizuho Top Stock Gainers Today – QS, JOBY, and More View Source19: Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease View Source20: Lantheus acquires Meilleur Technologies, gaining Alzheimer's imaging agent candidate View Source21: Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease Lantheus announces acquisition of Meilleur Technologies, NAV-4694 Lantheus price target raised to $165 from $100 at Mizuho Top Stock Gainers Today – QS, JOBY, and More View Source22: Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease View Source23: Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers View Source24: Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform View Source25: Justin Walsh has given his Buy rating due to a combination of factors that underscore Lantheus Holdings, Inc.’s promising outlook. The recent proposed changes to the CMS rules have led to a positive adjustment in the sales trajectory for PYLARIFY, Lantheus’s diagnostic agent, which has improved the company’s future revenue projections. Walsh’s confidence is solidified by a risk-adjusted discounted cash flow analysis, which suggests an increase in the fair market capitalization of Lantheus, prompting an increase in the 12-month price target for the stock from $128 to $137. Moreover, the strategic acquisition of Meilleur Technologies by Lantheus is indicative of the company’s commitment to expanding its portfolio and pipeline, particularly within the therapeutic radiopharmaceutical space. This expansion is expected to be a key driver of medium- to long-term value. Despite the CMS rule changes benefiting PYLARIFY sales, Walsh emphasizes that the company’s growth potential lies in its therapeutic offerings, which are projected to account for a significant portion of future revenues—underscoring the company’s promising financial trajectory and justifying the Buy rating. View Source